Top Rated Report: Global Market Study on Diabetic Nephropathy Asia to Witness Highest Growth by 2020
The increasing R&D investment in drug discovery and development and rising incidences of obesity are major factors adding growth to the market. Another growth factor is the heightened awareness about the diabetes and kidney-related disorders among people. Today, more people are being diagnosed with diabetes not just in developed regions but also in the emerging countries of the world.
Browse
Full Report With TOC: http://www.mrrse.com/reports/diabetic-nephropathy-market
the past few years, a number of established players have made huge
investments in the field of drug discovery and neuropathy R&D. Sanofi has a
strong hold in the global diabetic nephropathy market in terms of drug
discoveries and modes of treatments. Other market players such as the Eli Lilly
and Company, Mitsubishi Tanabe Pharma, Pfizer, Inc., Novartis AG, Abbott
Laboratories, Reata Pharmaceuticals, Inc., Merck & Co., Inc., AbbVie, Inc.,
and Bayer AG also hold smaller shares of market revenue in the global diabetic
nephropathy market.
The global market for diabetic nephropathy is classified into
disease modifying therapy (DMT). DMT is the fastest developing mode of treatment
for diabetic nephropathy. DMT is broadly sub-divided into rennin inhibitors,
diuretics, ACE inhibitors, G protein-coupled receptors, antioxidant
inflammation modulators, ARBs, calcium channel blockers, and monocyte
chemoattractant protein inhibitors.
To
Get Download Full Report with TOC: http://www.mrrse.com/enquiry/diabetic-nephropathy-market
The global market for diabetic nephropathy is classified into
disease modifying therapy (DMT). DMT is the fastest developing mode of
treatment for diabetic nephropathy. DMT is broadly sub-divided into rennin
inhibitors, diuretics, ACE inhibitors, G protein-coupled receptors, antioxidant
inflammation modulators, ARBs, calcium channel blockers, and monocyte
chemoattractant protein inhibitors.
The need for comprehensive therapeutic management is projected to
be the future of the diabetic nephropathy market. Comprehensive therapeutic
management could be harnessed as a growing opportunity by several market
participants in the next five years. However, presently, there is a lack of
awareness regarding this treatment in many regions of the world. This market
scenario is likely to change by 2020, predict the leading research analysts in the
report.
Preview
Analysis:
Diabetic nephropathy is a kidney disorder. When diabetes damages
the kidneys, it results in diabetic nephropathy. Diabetic nephropathy is one of
the major complications in terms of mortality and morbidity for both type 1 and
type 2 diabetic patients. Diabetic nephropathy can also be caused by
hypertension, imbalanced glomerular filtration rate, and proteinuria. The
treatments used to prevent the growth of diabetic nephropathy are blood
pressure control and glycemic control. Diabetic neuropathy could also be
controlled by diagnosing the condition at an initial stage and educating
patients for regular check-ups.
The global market for diabetic nephropathy will undergo a number
of changes until 2020. These changes are expected to be in terms of new product
developments and the way diabetes management is considered for treating
diabetic nephropathy.
The treatment guidelines set by ‘The American Diabetes Association
(ADA)’ for diabetic nephropathy focuses on maintaining near-normal levels of
blood glucose and decreasing blood pressure (BP). These factors help to reduce
the risk of diabetic nephropathy. The ADA also provides recommendations for
pharmacologic interventions and lifestyle modifications such as angiotensin
receptor blockers (ARBs) and angiotensin-converting-enzyme inhibitors (ACEs).
In the U.S., diabetic nephropathy is the leading cause of end-stage renal
disease (ESRD) and around 40% of new cases have been reported in the recent
past, added ADA.
According to the International Diabetes Federation (IDF), Asia is
expected to witness highest growth by 2020. The developing countries such as
China and India in Asia are expected to have the highest number of diabetes
mellitus patients as compared to countries such as Germany and the U.S. Asia is
the fastest growing region in the diabetic nephropathy market due to the rising
diabetic population in Southeast Asia, especially in countries such as Japan.
The report provides in-depth analysis and estimation of the
diabetic nephropathy market in Asia over the forecast period between 2014 and
2020, considering 2013 as the base year for calculation.
Contact Us
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Toll Free: 866-997-4948
(USA-CANADA)
Tel: +1-518-618-1030
Websites: http://www.mrrse.com/
Email: sales@mrrse.com
Comments
Post a Comment